RU2017145095A - Фармацевтические композиции - Google Patents

Фармацевтические композиции Download PDF

Info

Publication number
RU2017145095A
RU2017145095A RU2017145095A RU2017145095A RU2017145095A RU 2017145095 A RU2017145095 A RU 2017145095A RU 2017145095 A RU2017145095 A RU 2017145095A RU 2017145095 A RU2017145095 A RU 2017145095A RU 2017145095 A RU2017145095 A RU 2017145095A
Authority
RU
Russia
Prior art keywords
pharmaceutical composition
composition according
weight
lubricant
mannitol
Prior art date
Application number
RU2017145095A
Other languages
English (en)
Russian (ru)
Other versions
RU2017145095A3 (enExample
Inventor
Сара Элизабет ДЭВИД
Кристиан КАМИНСКИ
Original Assignee
Новартис Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56081526&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2017145095(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Новартис Аг filed Critical Новартис Аг
Publication of RU2017145095A publication Critical patent/RU2017145095A/ru
Publication of RU2017145095A3 publication Critical patent/RU2017145095A3/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2893—Tablet coating processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/485—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
RU2017145095A 2015-05-22 2016-05-19 Фармацевтические композиции RU2017145095A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562165333P 2015-05-22 2015-05-22
US62/165,333 2015-05-22
PCT/IB2016/052943 WO2016189435A1 (en) 2015-05-22 2016-05-19 Pharmaceutical compositions

Publications (2)

Publication Number Publication Date
RU2017145095A true RU2017145095A (ru) 2019-06-24
RU2017145095A3 RU2017145095A3 (enExample) 2019-10-25

Family

ID=56081526

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017145095A RU2017145095A (ru) 2015-05-22 2016-05-19 Фармацевтические композиции

Country Status (15)

Country Link
US (1) US20180153899A1 (enExample)
EP (1) EP3297609A1 (enExample)
JP (1) JP2018515566A (enExample)
KR (1) KR20180008511A (enExample)
CN (1) CN107847448A (enExample)
AU (1) AU2016268477B2 (enExample)
BR (1) BR112017024337A2 (enExample)
CA (1) CA2986522A1 (enExample)
CL (1) CL2017002948A1 (enExample)
HK (1) HK1245073A1 (enExample)
IL (1) IL255510A (enExample)
MX (1) MX2017014987A (enExample)
PH (1) PH12017502017A1 (enExample)
RU (1) RU2017145095A (enExample)
WO (1) WO2016189435A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110831582B (zh) * 2017-07-05 2023-08-11 诺华股份有限公司 药物组合物
KR20190089668A (ko) 2018-01-23 2019-07-31 현대모비스 주식회사 브레이크 장치용 패드 라이너
KR20200043618A (ko) 2018-10-18 2020-04-28 주식회사유한양행 아미노피리미딘 유도체 또는 이의 염을 포함하는 경구투여용 약학 조성물
CN115974803B (zh) * 2022-12-12 2024-04-09 渐宽(苏州)生物科技有限公司 一种普赛莫德的晶型及其制备方法和用途

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3782612T3 (da) * 2008-05-15 2024-01-15 Celgene Corp Orale formuleringer af cytidinanaloger og fremgangsmåder til anvendelse deraf
US20120059011A1 (en) * 2009-06-15 2012-03-08 Nicholas Birringer Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
AR081776A1 (es) * 2010-06-30 2012-10-17 Novartis Ag Composiciones farmaceuticas que comprenden monohidrato de lactato de 4-amino-5-fluoro-3-[6-(4-metil-piperazin-1-il)-1h-bencimidazol-2-il]-1h-quinolin-2-ona, proceso para la produccion de la composicion
JO3300B1 (ar) * 2012-06-06 2018-09-16 Novartis Ag مركبات وتركيبات لتعديل نشاط egfr
US9675587B2 (en) * 2013-03-14 2017-06-13 Allergan Holdings Unlimited Company Opioid receptor modulator dosage formulations

Also Published As

Publication number Publication date
RU2017145095A3 (enExample) 2019-10-25
JP2018515566A (ja) 2018-06-14
AU2016268477B2 (en) 2018-12-20
WO2016189435A1 (en) 2016-12-01
HK1245073A1 (zh) 2018-08-24
MX2017014987A (es) 2018-04-13
KR20180008511A (ko) 2018-01-24
US20180153899A1 (en) 2018-06-07
PH12017502017A1 (en) 2018-04-02
IL255510A (en) 2018-04-30
BR112017024337A2 (pt) 2018-07-31
AU2016268477A1 (en) 2017-11-30
CL2017002948A1 (es) 2018-05-18
CN107847448A (zh) 2018-03-27
CA2986522A1 (en) 2016-12-01
EP3297609A1 (en) 2018-03-28

Similar Documents

Publication Publication Date Title
ES2582646T5 (es) Formulación de comprimido recubierto y método
EP3606511B1 (en) Pharmaceutical composition comprising lenvatinib mesylate
WO2018228441A1 (zh) 一种控释药物组合物及其制备方法
US11266628B2 (en) Pharmaceutical compositions of apremilast
TWI739756B (zh) 一種含有喹啉衍生物或其鹽的醫藥組成物
CA2915432C (en) Disintegrant free composition of cinacalcet
WO2012087255A2 (en) Pharmaceutical formulations
TW201717937A (zh) 含有芳基烷基胺化合物之醫藥組合物
JPWO2012018056A1 (ja) 圧縮組成物
EP3632436B1 (en) Pharmaceutical composition comprising lenvatinib salts
AU2016231883B2 (en) Pharmaceutical compositions of dimethyl fumarate
RU2642934C2 (ru) Капсульный состав
US20140010883A1 (en) Controlled release pharmaceutical compositions of selective serotonin reuptake inhibitor
JP2017048174A (ja) 化学的に安定な原薬含有被覆粒子を含む口腔内崩壊錠剤
JP2018515566A5 (enExample)
US20150140101A1 (en) Solid oral compositions of silodosin
MD4877C1 (ro) Compoziţie farmaceutică şi comprimat oral de S-adenozilmetionină cu eliberare întârziată
EA033685B1 (ru) Фармацевтические лекарственные формы
EP3332770A1 (en) Pharmaceutical compositions of dabigatran
JP6336651B1 (ja) 化学的安定性が改善されたエソメプラゾール塩を含有する錠剤
JP2016138073A (ja) 安定性を改善した、シロドシンを含有する錠剤
US20200215002A1 (en) Pharmaceutical compositions comprising cinacalcet hydrochloride and one or more binders
CZ29330U1 (cs) Pevná farmaceutická dávková forma obsahující kyselinu obeticholovou
US20170119678A1 (en) Extended release compositions of carvedilol phosphate

Legal Events

Date Code Title Description
FA92 Acknowledgement of application withdrawn (lack of supplementary materials submitted)

Effective date: 20200730